O Knesl1, F J Allan, S Shields. 1. Pfizer Animal Health, 685 3rd Avenue, Mail Stop 235 East 42mz Street 685/9/MS1, New York, NY 10017, USA. oliver.knesl@pfizer.com
Abstract
AIM: To determine whether canine respiratory coronavirus (CRCoV) and canine influenza virus (CIV) are present in dogs in New Zealand. METHODS: Serum samples from 251 dogs of varying age, breed and clinical histories were tested for the presence of antibodies to CRCoV and CIV, using indirect fluorescent antibody (IFA) analysis. The population sampled represented a wide geographic area but principally encompassed the central and lower North Island of New Zealand. RESULTS: Seventy-three of the 251 samples (29%) were seropositive for CRCoV. Dogs <2 years old were less likely to be seropositive for CRCoV than older dogs. None was seropositive for CIV. CONCLUSIONS: This study revealed the presence of antibodies to CRCoV in dogs in New Zealand. Young dogs are less likely to be seropositive than older dogs, probably due to increased opportunity for exposure to CRCoV over time. Serum antibodies to CIV were not detected in any of the dogs sampled, suggesting that this virus is unlikely to be present in dogs in New Zealand. CLINICAL RELEVENCE: Canine respiratory coronavirus is present in New Zealand. Although the role of this virus in canine infectious tracheobronchitis has not been fully elucidated, evidence suggests that it may have a causal role in this disease. Veterinarians should consider CRCoV as a differential diagnosis in cases of respiratory disease in dogs in New Zealand. While CIV appears not to be currently present in New Zealand, veterinarians should consider infection with this virus as a differential diagnosis in dogs presenting with respiratory signs.
AIM: To determine whether canine respiratory coronavirus (CRCoV) and canineinfluenza virus (CIV) are present in dogs in New Zealand. METHODS: Serum samples from 251 dogs of varying age, breed and clinical histories were tested for the presence of antibodies to CRCoV and CIV, using indirect fluorescent antibody (IFA) analysis. The population sampled represented a wide geographic area but principally encompassed the central and lower North Island of New Zealand. RESULTS: Seventy-three of the 251 samples (29%) were seropositive for CRCoV. Dogs <2 years old were less likely to be seropositive for CRCoV than older dogs. None was seropositive for CIV. CONCLUSIONS: This study revealed the presence of antibodies to CRCoV in dogs in New Zealand. Young dogs are less likely to be seropositive than older dogs, probably due to increased opportunity for exposure to CRCoV over time. Serum antibodies to CIV were not detected in any of the dogs sampled, suggesting that this virus is unlikely to be present in dogs in New Zealand. CLINICAL RELEVENCE: Canine respiratory coronavirus is present in New Zealand. Although the role of this virus in canineinfectious tracheobronchitis has not been fully elucidated, evidence suggests that it may have a causal role in this disease. Veterinarians should consider CRCoV as a differential diagnosis in cases of respiratory disease in dogs in New Zealand. While CIV appears not to be currently present in New Zealand, veterinarians should consider infection with this virus as a differential diagnosis in dogs presenting with respiratory signs.
Authors: Tara C Anderson; P Cynda Crawford; Jacqueline M Katz; Edward J Dubovi; Gabriele Landolt; E Paul J Gibbs Journal: J Vet Diagn Invest Date: 2012-05 Impact factor: 1.279
Authors: Jan Jurgiel; Krzysztof J Filipiak; Łukasz Szarpak; Miłosz Jaguszewski; Jacek Smereka; Tomasz Dzieciątkowski Journal: Med Hypotheses Date: 2020-05-12 Impact factor: 1.538
Authors: Judy A Mitchell; Harriet W Brooks; Balázs Szladovits; Kerstin Erles; Rachel Gibbons; Shelly Shields; Joe Brownlie Journal: Vet Microbiol Date: 2012-11-29 Impact factor: 3.293